Table 1.
Tumor and treatment characteristics among 4,283 white and 615 black women with endometrial carcinoma in the NRG Oncology/GOG 210 Study
| Race, n (%) | |||
|---|---|---|---|
| White | Black | P1 | |
| n=4,283 | n=615 | ||
| Tumor subtype | <.0001 | ||
| Low-grade endometrioid | 2392 (55.9) | 221 (35.9) | |
| High-grade endometrioid | 525 (12.3) | 68 (11.1) | |
| Serous | 522 (12.2) | 155 (25.2) | |
| Mixed cell | 467 (10.9) | 69 (11.2) | |
| Carcinosarcoma | 241 (5.6) | 71 (11.5) | |
| Clear cell | 135 (3.2) | 31 (5.0) | |
| Stage | <.0001 | ||
| I | 3090 (72.2) | 377 (61.3) | |
| II | 299 (7.0) | 61 (9.9) | |
| III | 700 (16.3) | 137 (22.3) | |
| IV | 194 (4.5) | 40 (6.5) | |
| Myometrial invasion | 0.06 | ||
| Negative | 1060 (24.7) | 140 (22.8) | |
| Inner half | 1987 (46.4) | 310 (50.4) | |
| Outer half | 1018 (23.8) | 131 (21.3) | |
| Serosa | 95 (2.2) | 21 (3.4) | |
| Not assessed/not reported | 123 (2.9) | 13 (2.1) | |
| Pelvic lymph node involvement | <.0001 | ||
| No | 3512 (82.0) | 458 (74.5) | |
| Yes | 482 (11.2) | 102 (16.6) | |
| Not assessed/not reported | 289 (6.8) | 55 (8.9) | |
| Aortic lymph node involvement | <.0001 | ||
| No | 3537 (82.6) | 455 (74.0) | |
| Yes | 262 (6.1) | 68 (11.1) | |
| Not assessed/not reported | 484 (11.3) | 92 (15.0) | |
| Peritoneal cytology | 0.09 | ||
| Negative | 3557 (83.0) | 489 (79.5) | |
| Positive | 447 (10.4) | 80 (13.0) | |
| Not assessed/not reported | 279 (6.5) | 46 (7.5) | |
| Peritoneal biopsy | <.0001 | ||
| Negative | 1716 (40.1) | 319 (51.9) | |
| Positive | 129 (3.0) | 22 (3.6) | |
| Not assessed/not reported | 2438 (56.9) | 274 (44.5) | |
| Complete surgical staging | 0.01 | ||
| No | 642 (15.0) | 116 (18.9) | |
| Yes | 3641 (85.0) | 499 (81.1) | |
| European Society for Medical Oncology risk category | <.0001 | ||
| Low-risk | 1687 (39.9) | 163 (26.7) | |
| Intermediate-risk | 525 (12.4) | 47 (7.7) | |
| High-risk | 2011 (47.6) | 401 (65.6) | |
| Unknown2 | 60 (1.4) | 4 (0.6) | |
| Adjuvant treatment | <.0001 | ||
| None | 2381 (55.6) | 278 (45.2) | |
| Radiotherapy only | 714 (16.7) | 92 (15.0) | |
| Chemotherapy only | 635 (14.8) | 110 (17.9) | |
| Radiotherapy plus chemotherapy | 553 (12.9) | 135 (22.0) | |
1
P value was from two-sided χ2 test
2
64 women were missing information on myometrial invasion and could not be categorized